FDA approves first-in-class therapy for polycythemia vera
The approval was supported by results from the global randomized phase 3 VERIFY trial involving 293 patients, which showed that patients receiving rusfertide
Myeloproliferative Neoplasms
Polycythemia Vera
News
SOHO 2026
News
Society Updates
What is the SOHO Ambassador program?
In this SOHO Insider video interview, Elias Jabbour, MD, professor of medicine in the department of leukemia at The University of Texas MD
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Where do CELMoDs, including mezigdomide and iberdomide, fit in the myeloma treatment landscape?
Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained. "We have very interesting maintenance trials,"
Trending now
Leukemia
Myelodysplastic Syndromes
News
FDA approves first targeted therapy for warm autoimmune hemolytic anemia
The approval is based on the Phase 2/3 ENERGY study, the full results of which were presented at the European Hematology Association 2026
Multiple Myeloma
News
NMPA grants approval to felzartamab in multiple myeloma
The China National Medical Products Administration (NMPA) has approved felzartamab (Jingfei), a human monoclonal antibody targeting CD38, in combination with lenalidomide and dexamethasone
EHA 2026
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
News
Video Interviews
Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL
He explains how this in vivo lentiviral vector infusion aims to eliminate traditional manufacturing barriers by shifting the cell engineering process directly into
Leukemia
Chronic Lymphocytic Leukemia
News
Partnership expands access to CLL treatment in low-, middle-income countries
To date, the initiative has enabled access to the treatment for more than 300 patients across Armenia, Ethiopia, and Nepal, exceeding its original
Multiple Myeloma
News
FDA grants accelerated approval to iberdomide combo in multiple myeloma
...the approval is based on results from the Phase 3 EXCALIBER-RRMM trial, which showed iberdomide significantly improved minimal residual disease (MRD)-negative complete response
ASCO 2026
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Video Interviews
Fedratinib demonstrates favorable OS in MDS/MPN overlap syndrome
The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months,
News
NICE recommends acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukemia
The draft guidance expands frontline options for patients who are ineligible for stem cell transplants or who require oral therapies.